DNLI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Denali Therapeutics Inc (DNLI) is not an ideal buy for a beginner investor with a long-term strategy at this moment. While the company has positive developments, such as FDA approvals and raised price targets, the lack of strong financial performance, insider selling, and no significant trading signals suggest waiting for a more stable entry point.
The technical indicators are mixed. The MACD is slightly positive but contracting, RSI is neutral at 37.124, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its support level of 19.24, with resistance levels at 21.41 and 22.08. The recent price action shows a -3.95% drop in the regular market, with a slight recovery in post-market trading (+1.95%).
FDA accelerated approval for Avlayah, which validates the company's platform and transitions it to a commercial stage.
Analysts have raised price targets significantly, with targets ranging from $31 to $42, reflecting optimism about the company's future prospects.
Promising pipeline assets like DNL-593 and DNL-126 for neurological disorders.
Insiders are selling heavily, with an 844.50% increase in selling activity over the last month.
Financials are weak, with negative net income (-$128.5M) and EPS (-0.73), despite slight YoY improvement.
Hedge funds remain neutral, and there are no significant trading trends.
No recent congress trading data or influential figure involvement.
In Q4 2025, the company reported zero revenue growth (0.00% YoY) and a net loss of $128.5M, though net income improved by 12.02% YoY. EPS also improved by 8.96% YoY to -0.73. Gross margin remains at 0, indicating no profitability.
Analysts are optimistic, with multiple firms raising price targets recently. These range from $31 to $42, with most firms maintaining Buy or Outperform ratings. The FDA approval of Avlayah and regaining full control of DNL-593 are key drivers of this optimism.
